Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 15.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Investoren zahlen Prämie: Fura Gems schließt Kapitalrunde über 26,8 Mio. CAD ab
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
28.09.2018 | 13:19
(40 Leser)
(0 Bewertungen)
SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc. Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX." The Company's website will be accessible at www.anixa.com.

Amit Kumar, the Company's CEO stated, "We are focused on making advances in the biotechnology field. We began in diagnostics with development of the Cchek™ platform for early detection of cancer and are expanding into cancer therapeutics as we develop our CAR-T therapy for ovarian cancer. We believe the name Anixa Biosciences more accurately reflects this focus and clearly identifies us as biotech company. The ITUS name is more reflective of our legacy operations."

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. ITUS is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

SOURCE ITUS Corporation
Related Links

http://www.ituscorp.com

© 2018 PR Newswire